KARL PLEASANT: Open Payments
NPI 1982628145 · WINSTON SALEM, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,089 in 45 payments from 13 companies in 2025. Trend: 2023 $396 · 2024 $1,213 · 2025 $1,089
Food & beverage: $1,089
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 5 | $208 |
| Ardelyx, Inc. | 11 | $183 |
| ABBVIE INC. | 8 | $158 |
| Janssen Biotech, Inc. | 1 | $88 |
| Phathom Pharmaceuticals, Inc. | 4 | $68 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $67 |
| PFIZER INC. | 3 | $61 |
| Aimmune Therapeutics, Inc. | 2 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $51 |
| GENZYME CORPORATION | 2 | $49 |
Products named: REZDIFFRA, IBSRELA, TREMFYA, DUPIXENT, VOQUEZNA, XIFAXAN, LINZESS, RINVOQ.
Industry payments across NC — which companies pay providers there.
